Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: Chabon, Jacob J., Simmons, Andrew D., Lovejoy, Alexander F., Esfahani, Mohammad S., Newman, Aaron M., Haringsma, Henry J., Kurtz, David M., Stehr, Henning, Scherer, Florian, Karlovich, Chris A., Harding, Thomas C., Durkin, Kathleen A., Otterson, Gregory A., Purcell, W. Thomas, Camidge, D. Ross, Goldman, Jonathan W., Sequist, Lecia V., Piotrowska, Zofia, Wakelee, Heather A., Neal, Joel W., Alizadeh, Ash A., Diehn, Maximilian
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4906406/
https://ncbi.nlm.nih.gov/pubmed/27283993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11815
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares